NovoCure Limited (NVCR) 10-Q2022 Q1 Quarterly report

Filed: 28 Apr 22, 7:03am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: adapt, agency, broader, classification, comprehensive, corporate, daily, declared, direct, evolving, flat, fluctuate, forecasted, German, globe, government, governmental, hold, implemented, indirectly, interbank, Kingdom, local, localized, met, onset, physical, Prevention, procured, recovery, remaining, resident, rest, roughly, sample, situation, size, subsidiary, transferring, turnover, UK, unrealized, vaccine, working

Removed: absence, account, accrual, adjustment, advanced, adverse, application, approach, April, asset, ASU, Austria, beginning, bifurcation, billed, Board, Codification, comment, continued, deferred, derivative, developing, dialogue, dose, embedded, EPS, established, establishing, evidence, FASB, feature, flow, focused, France, fully, funding, generating, half, Hedging, HEPANOVA, IDE, important, incorporating, influence, informed, inhibitor, initiate, instrument, investigating, investigational, Israel, July, KEYNOTE, kinase, leader, length, LIBOR, liver, long, longer, LUNAR, measured, Medicare, Merck, modified, MSD, observed, original, path, payable, pembrolizumab, policy, positive, potentially, power, preclinical, premium, prepaid, present, prioritize, professional, proposed, protocol, Quoted, receipt, recently, reduced, repayment, require, response, retrospective, review, separately, separation, Similarly, Simplifying, sorafenib, substantial, successful, supplement, Sweden, systemic, test, Topic, toxicity, tradename, trial, TRIDENT, unethical, unnecessary, variance, wholly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated NVCR transcripts

NVCR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

NOVOCURE LIMITED

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of NovoCure Limited (the "Company") on Form 10-Q for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Asaf Danziger, Chief Executive Officer (Principal Executive Officer) of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


/s/ Asaf Danziger
Asaf Danziger
Chief Executive Officer
(Principal Executive Officer)

Date: April 28, 2022

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff on request.

This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of NovoCure Limited under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.